The potential value of fatty acid binding protein 1 in Chronic HBV-related liver disease progression assessment.
Fatty acid binding protein1 (FABP1)
Fibrosis
Hepatitis B virus (HBV)
Inflammation
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
28 Oct 2024
28 Oct 2024
Historique:
received:
29
04
2024
accepted:
23
10
2024
medline:
29
10
2024
pubmed:
29
10
2024
entrez:
29
10
2024
Statut:
epublish
Résumé
Fatty acid binding protein 1 (FABP1), a low molecular weight intracellular protein, has been proposed as a potential useful serum biomarker for liver injury. However, limited investigations have been conducted in chronic hepatitis B virus (HBV)-related liver disease. To investigate the diagnostic potential of FABP1 in disease progression among patients with chronic HBV-related liver disease. A prospective study was conducted on 293 patients with chronic HBV-related liver diseases, including chronic asymptomatic carrier (ASC), chronic hepatitis B (CHB). FABP1 was measured in serum samples collected at admission and some selected liver biopsies. Immunohistochemical analysis revealed abundant cytoplasmic expression of FABP1 in hepatocytes. A significant negative correlation was observed between FABP1 expression and inflammation grades in liver tissue (Spearman's r = -0.355, P = 0.017). However, no statistically significant correlation was found with fibrosis (P > 0.05). Serum FABP1 levels in the case group were significantly higher than in the healthy control (HC) group [median: 804.2 (687.8, 939.2) vs. 709.1 (626.2, 807.8) ng/ml, Z = -5.505, P < 0.001] and showed correlations with alanine aminotransferase (ALT), aspartate aminotransferase (AST); total bilirubin (TBIL); direct bilirubin (DBIL); albumin (ALB), etc. Its levels progressively increased with the advancement from ASC to CHB, with significant differences compared to the HC group (P < 0.001), especially in ASC patients with high HBV DNA (exceeding 10 Our study demonstrated a significant inverse correlation between FABP1 levels and the severity of inflammation grades in patients with HBV-related liver diseases. Furthermore, elevated serum FABP1 levels were observed in these patients, suggesting its potential as a biomarker for assessing HBV-related liver damage to initiate antiviral therapy. Additionally, further evaluation is required to determine its potential as a biomarker for assessing disease severity.
Sections du résumé
BACKGROUND
BACKGROUND
Fatty acid binding protein 1 (FABP1), a low molecular weight intracellular protein, has been proposed as a potential useful serum biomarker for liver injury. However, limited investigations have been conducted in chronic hepatitis B virus (HBV)-related liver disease.
OBJECTIVE
OBJECTIVE
To investigate the diagnostic potential of FABP1 in disease progression among patients with chronic HBV-related liver disease.
METHODS
METHODS
A prospective study was conducted on 293 patients with chronic HBV-related liver diseases, including chronic asymptomatic carrier (ASC), chronic hepatitis B (CHB). FABP1 was measured in serum samples collected at admission and some selected liver biopsies.
RESULTS
RESULTS
Immunohistochemical analysis revealed abundant cytoplasmic expression of FABP1 in hepatocytes. A significant negative correlation was observed between FABP1 expression and inflammation grades in liver tissue (Spearman's r = -0.355, P = 0.017). However, no statistically significant correlation was found with fibrosis (P > 0.05). Serum FABP1 levels in the case group were significantly higher than in the healthy control (HC) group [median: 804.2 (687.8, 939.2) vs. 709.1 (626.2, 807.8) ng/ml, Z = -5.505, P < 0.001] and showed correlations with alanine aminotransferase (ALT), aspartate aminotransferase (AST); total bilirubin (TBIL); direct bilirubin (DBIL); albumin (ALB), etc. Its levels progressively increased with the advancement from ASC to CHB, with significant differences compared to the HC group (P < 0.001), especially in ASC patients with high HBV DNA (exceeding 10
CONCLUSION
CONCLUSIONS
Our study demonstrated a significant inverse correlation between FABP1 levels and the severity of inflammation grades in patients with HBV-related liver diseases. Furthermore, elevated serum FABP1 levels were observed in these patients, suggesting its potential as a biomarker for assessing HBV-related liver damage to initiate antiviral therapy. Additionally, further evaluation is required to determine its potential as a biomarker for assessing disease severity.
Identifiants
pubmed: 39468469
doi: 10.1186/s12879-024-10114-8
pii: 10.1186/s12879-024-10114-8
doi:
Substances chimiques
Fatty Acid-Binding Proteins
0
Biomarkers
0
FABP1 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1214Informations de copyright
© 2024. The Author(s).
Références
Jeng WJ, Papatheodoridis GV, Lok ASF. Hepatitis B. Lancet. 2023;401(10381):1039–52.
pubmed: 36774930
doi: 10.1016/S0140-6736(22)01468-4
Hsu YC, Huang DQ, Nguyen MH. Global burden of hepatitis B virus: current status, missed opportunities and a call for action. Nat Rev Gastroenterol Hepatol. 2023;20(8):524–37.
pubmed: 37024566
doi: 10.1038/s41575-023-00760-9
Zhang C, Li JW, Wu Z, Zhao H, Wang GQ. Significant Histologic Changes Are Not Rare in Treatment-naive Hepatitis B Patients with Normal Alanine Aminotransferase Level: A Meta-analysis. J Clin Transl Hepatol. 2021;9(5):615–25.
pubmed: 34722176
pmcid: 8516830
Wu Z, Ma AL, Xie Q, Zhang XQ, Cheng J, Zhang DZ, Wang GQ, Zhao H. Significant histological changes and satisfying antiviral efficacy in chronic hepatitis B virus infection patients with normal alanine aminotransferase. Antiviral therapy decision in chronic HBV patients with normal ALT. Clin Res Hepatol Gastroenterol. 2021;45(2):101463.
pubmed: 32571749
doi: 10.1016/j.clinre.2020.05.011
Kim GA, Lim YS, Han S, Choi J, Shim JH, Kim KM, Lee HC, Lee YS. High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B. Gut. 2018;67(5):945–52.
pubmed: 29055908
doi: 10.1136/gutjnl-2017-314904
Huang R, Liu J, Wang J, Qiu Y, Zhu L, Li Y, Liu Y, Zhan J, Xue R, Jiang S, et al. Histological features of chronic hepatitis B patients with normal alanine aminotransferase according to different criteria. Hepatol Commun. 2024;8(1):e0357.
You H, Sun YM, Zhang MY, Nan YM, Xu XY, Li TS, Wang GQ, Hou JL, Duan ZP, Wei L, et al. [Interpretation of the essential updates in guidelines for the prevention and treatment of chronic hepatitis B (Version 2022)]. Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese j hepatol. 2023;31(4):385–8.
Zhou J, Wang F, Li L, Chen E. Expanding antiviral therapy indications for HBeAg-negative chronic hepatitis B patients with normal ALT and positive HBV DNA. Precision clin med. 2022;5(4):pbac030.
doi: 10.1093/pcmedi/pbac030
Xu K, Liu LM, Farazi PA, Wang H, Rochling FA, Watanabe-Galloway S, Zhang JJ. Adherence and perceived barriers to oral antiviral therapy for chronic hepatitis B. Glob Health Action. 2018;11(1):1433987.
pubmed: 29447614
pmcid: 5827725
doi: 10.1080/16549716.2018.1433987
Shi H, Xiao G, Liao M, Zheng L, Jie Y, Lin G, Chong Y. Inappropriate cessation of nucleos(t)ide analog associated with reduced liver transplant-free survival in patients with HBV-related acute on chronic liver failure. Biomed pharmacother = Biomed pharmacother. 2021;134:111118.
pubmed: 33341047
doi: 10.1016/j.biopha.2020.111118
Wang XH, Jiang XM, Gao PX, Liu Q, Yuan JH, Chen SJ. Risk factors and prognostic analysis of acute-on-chronic liver failure of chronic hepatitis B after cessation of nucleos(t)ide analogs. Eur J Gastroenterol Hepatol. 2020;32(2):265–75.
pubmed: 31789948
doi: 10.1097/MEG.0000000000001574
Hsu YC, Lin YH, Lee TY, Nguyen MH, Tseng CH, Ho HJ, Kao FY, Lin JT, Wu CY, Wu CY. Severe hepatitis B flares with hepatic decompensation after withdrawal of nucleos(t)ide analogues: A population-based cohort study. Aliment Pharmacol Ther. 2023;58(4):463–73.
pubmed: 37341016
doi: 10.1111/apt.17614
Chong CH, Lim SG. When can we stop nucleoside analogues in patients with chronic hepatitis B? Liver international : official journal of the International Association for the Study of the Liver. 2017;37(Suppl 1):52–8.
pubmed: 28052620
doi: 10.1111/liv.13314
Ovchinsky N, Moreira RK, Lefkowitch JH, Lavine JE. Liver biopsy in modern clinical practice: a pediatric point-of-view. Adv Anat Pathol. 2012;19(4):250–62.
pubmed: 22692288
pmcid: 3404724
doi: 10.1097/PAP.0b013e31825c6a20
Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD. American Association for the Study of Liver D: Liver biopsy. Hepatology. 2009;49(3):1017–44.
pubmed: 19243014
doi: 10.1002/hep.22742
van den Broek MA, Bloemen JG, Dello SA, van de Poll MC, Olde Damink SW, Dejong CH. Randomized controlled trial analyzing the effect of 15 or 30 min intermittent Pringle maneuver on hepatocellular damage during liver surgery. J Hepatol. 2011;55(2):337–45.
pubmed: 21147188
doi: 10.1016/j.jhep.2010.11.024
Monbaliu D, de Vries B, Crabbe T, van Heurn E, Verwaest C, Roskams T, Fevery J, Pirenne J, Buurman WA. Liver fatty acid-binding protein: an early and sensitive plasma marker of hepatocellular damage and a reliable predictor of graft viability after liver transplantation from non-heart-beating donors. Transpl Proc. 2005;37(1):413–6.
doi: 10.1016/j.transproceed.2004.12.103
Pelsers MM, Morovat A, Alexander GJ, Hermens WT, Trull AK, Glatz JF. Liver fatty acid-binding protein as a sensitive serum marker of acute hepatocellular damage in liver transplant recipients. Clin Chem. 2002;48(11):2055–7.
pubmed: 12406996
doi: 10.1093/clinchem/48.11.2055
Akbal E, Koklu S, Kocak E, Cakal B, Gunes F, Basar O, Tuna Y, Senes M. Liver fatty acid-binding protein is a diagnostic marker to detect liver injury due to chronic hepatitis C infection. Arch Med Res. 2013;44(1):34–8.
pubmed: 23291381
doi: 10.1016/j.arcmed.2012.11.007
Ozenirler S, Degertekin CK, Erkan G, Elbeg S, Tuncer C, Kandilc U, Akyol G. Serum liver fatty acid binding protein shows good correlation with liver histology in NASH. Hepatogastroenterology. 2013;60(125):1095–100.
pubmed: 23803374
Bierla JB, Janczyk W, Konopka E, Wierzbicka-Rucinska A, Wieckowski S, Obrycki L, Sarnecki J, Kanarek E, Cukrowska B, Socha P. Fatty Acid-Binding Protein 1 as a Potential New Serological Marker of Liver Status in Children with Wilson Disease. J Pediatr Gastroenterol Nutr. 2021;73(4):455–62.
Eguchi A, Iwasa M. The Role of Elevated Liver-Type Fatty Acid-Binding Proteins in Liver Diseases. Pharm Res. 2021;38(1):89–95.
pubmed: 33534129
doi: 10.1007/s11095-021-02998-x
Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol. 1991;13(3):372–4.
pubmed: 1808228
doi: 10.1016/0168-8278(91)90084-O
Hadziyannis SJ, Vassilopoulos D, Hadziyannis E. The natural course of chronic hepatitis B virus infection and its management. Adv Pharmacol. 2013;67:247–91.
pubmed: 23886003
doi: 10.1016/B978-0-12-405880-4.00007-X
Liu J, Wang J, Yan X, Xue R, Zhan J, Jiang S, Geng Y, Liu Y, Mao M, Xia J, et al. Presence of Liver Inflammation in Asian Patients With Chronic Hepatitis B With Normal ALT and Detectable HBV DNA in Absence of Liver Fibrosis. Hepatology communications. 2022;6(4):855–66.
pubmed: 34783181
doi: 10.1002/hep4.1859
Duan M, Chi X, Xiao H, Liu X, Zhuang H. High-normal alanine aminotransferase is an indicator for liver histopathology in HBeAg-negative chronic hepatitis B. Hep Intl. 2021;15(2):318–27.
doi: 10.1007/s12072-021-10153-2
Kang NL, Wu LY, Zheng Q, Yu XP, Hu AR, Guo Y, Li H, Ye XY, Ruan QF, Lu ZH, et al. Determining optimal ALT cut-off values for predicting significant hepatic histological changes in patients with normal ALT in the grey zone of chronic hepatitis B virus infection. Aliment Pharmacol Ther. 2024;59(5):692–704.
pubmed: 38178641
doi: 10.1111/apt.17862
Dufour DR, Lott JA, Nolte FS, Gretch DR, Koff RS, Seeff LB. Diagnosis and monitoring of hepatic injury. I. Performance characteristics of laboratory tests. Clin Chem. 2000;46(12):2027–49.
pubmed: 11106349
doi: 10.1093/clinchem/46.12.2027
van de Poll MC, Derikx JP, Buurman WA, Peters WH, Roelofs HM, Wigmore SJ, Dejong CH. Liver manipulation causes hepatocyte injury and precedes systemic inflammation in patients undergoing liver resection. World J Surg. 2007;31(10):2033–8.
pubmed: 17668263
pmcid: 2039834
doi: 10.1007/s00268-007-9182-4
Mikus M, Drobin K, Gry M, Bachmann J, Lindberg J, Yimer G, Aklillu E, Makonnen E, Aderaye G, Roach J, et al. Elevated levels of circulating CDH5 and FABP1 in association with human drug-induced liver injury. Liver international : official journal of the International Association for the Study of the Liver. 2017;37(1):132–40.
pubmed: 27224670
doi: 10.1111/liv.13174
Cheng X, Zhu J, Li Y, Luo W, Xiang H, Zhang Q, Peng W. Serum biomarkers of isoniazid-induced liver injury: Aminotransferases are insufficient, and OPN, L-FABP and HMGB1 can be promising novel biomarkers. Journal of applied toxicology : JAT. 2022;42(3):516–28.
pubmed: 34494278
doi: 10.1002/jat.4236
Peng XE, Wu YL, Lu QQ, Hu ZJ, Lin X. Two genetic variants in FABP1 and susceptibility to non-alcohol fatty liver disease in a Chinese population. Gene. 2012;500(1):54–8.
pubmed: 22465531
doi: 10.1016/j.gene.2012.03.050
Muthusamy G, Liu CC, Johnston AN. Deletion of PGAM5 Downregulates FABP1 and Attenuates Long-Chain Fatty Acid Uptake in Hepatocellular Carcinoma. Cancers. 2023;15(19):4796.
Cho SJ, Ferrell LD, Gill RM. Expression of liver fatty acid binding protein in hepatocellular carcinoma. Hum Pathol. 2016;50:135–9.
pubmed: 26997447
doi: 10.1016/j.humpath.2015.12.002
Karvellas CJ, Speiser JL, Tremblay M, Lee WM, Rose CF. Group USALFS: Elevated FABP1 serum levels are associated with poorer survival in acetaminophen-induced acute liver failure. Hepatology. 2017;65(3):938–49.
pubmed: 27859489
doi: 10.1002/hep.28945
Karvellas CJ, Speiser JL, Tremblay M, Lee WM, Rose CF. Group USALFS: Elevated Serum Liver-Type Fatty Acid Binding Protein Levels in Non-acetaminophen Acute Liver Failure Patients with Organ Dysfunction. Dig Dis Sci. 2021;66(1):273–83.
pubmed: 32125573
doi: 10.1007/s10620-020-06166-w
Rakela JL, Karvellas CJ, Koch DG, Vegunta S, Lee WM. Acute Liver Failure: Biomarkers Evaluated by the Acute Liver Failure Study Group. Clin Transl Gastroenterol. 2023;14(4): e00565.
pubmed: 36716224
pmcid: 10132708
doi: 10.14309/ctg.0000000000000565
Juanola A, Graupera I, Elia C, Piano S, Solé C, Carol M, Pérez-Guasch M, Bassegoda O, Escudé L, Rubio A, et al. Urinary L-FABP is a promising prognostic biomarker of ACLF and mortality in patients with decompensated cirrhosis. J Hepatol. 2022;76(1):107–14.
pubmed: 34530063
doi: 10.1016/j.jhep.2021.08.031
Chen A, Tang Y, Davis V, Hsu FF, Kennedy SM, Song H, Turk J, Brunt EM, Newberry EP, Davidson NO. Liver fatty acid binding protein (L-Fabp) modulates murine stellate cell activation and diet-induced nonalcoholic fatty liver disease. Hepatology. 2013;57(6):2202–12.
pubmed: 23401290
doi: 10.1002/hep.26318
Lin J, Zheng S, Attie AD, Keller MP, Bernlohr DA, Blaner WS, Newberry EP, Davidson NO, Chen A. Perilipin 5 and liver fatty acid binding protein function to restore quiescence in mouse hepatic stellate cells. J Lipid Res. 2018;59(3):416–28.
pubmed: 29317465
pmcid: 5832927
doi: 10.1194/jlr.M077487
Gui HL, Wang H, Yang YH, Wu YW, Zhou HJ, Guo SM, Lin LY, Wang L, Cai W, Chen R, et al. Significant histopathology in Chinese chronic hepatitis B patients with persistently high-normal alanine aminotransferase. J Viral Hepatitis. 2010;17(Suppl 1):44–50.
doi: 10.1111/j.1365-2893.2010.01270.x
Lu YC, Chang CC, Wang CP, Hung WC, Tsai IT, Tang WH, Wu CC, Wei CT, Chung FM, Lee YJ, et al. Circulating fatty acid-binding protein 1 (FABP1) and nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. Int J Med Sci. 2020;17(2):182–90.
pubmed: 32038102
pmcid: 6990891
doi: 10.7150/ijms.40417
Shi J, Zhang Y, Gu W, Cui B, Xu M, Yan Q, Wang W, Ning G, Hong J. Serum liver fatty acid binding protein levels correlate positively with obesity and insulin resistance in Chinese young adults. PLoS ONE. 2012;7(11): e48777.
pubmed: 23144966
pmcid: 3492433
doi: 10.1371/journal.pone.0048777
Newberry EP, Xie Y, Kennedy SM, Luo J, Davidson NO. Protection against Western diet-induced obesity and hepatic steatosis in liver fatty acid-binding protein knockout mice. Hepatology. 2006;44(5):1191–205.
pubmed: 17058218
doi: 10.1002/hep.21369
Newberry EP, Kennedy SM, Xie Y, Sternard BT, Luo J, Davidson NO. Diet-induced obesity and hepatic steatosis in L-Fabp / mice is abrogated with SF, but not PUFA, feeding and attenuated after cholesterol supplementation. Am J Physiol Gastrointest Liver Physiol. 2008;294(1):G307-314.
pubmed: 18032478
doi: 10.1152/ajpgi.00377.2007